Pfizer

Health
Covid-19: Pfizer and BioNTech vaccine offers 90% protection
Covid-19: Pfizer and BioNTech vaccine offers 90% protection
Credit: Illustration: Pendect, Logos Pfizer and BioNTech (Creative Commons Attribution ShareAlike 4.0)

According to a preliminary analysis, the vaccine developed by Pfizer and BioNTech can prevent more than 90% of people from getting Covid-19. However, the data presented is not the final analysis as it is based on only the first 94 volunteers to develop Covid-19 so the precise effectiveness of the vaccine may change when the full results are analysed.

The companies stated they would be able to supply 50 million doses by the end of this year and around 1.3 billion by the end of 2021. Each person needs two doses.

Dr Albert Bourla, the chairman of Pfizer, said: "We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis."

Business • Health Care
Nine biopharmaceutical companies sign safety pledge for Covid-19 vaccine
Nine biopharmaceutical companies sign safety pledge for Covid-19 vaccine
Credit: unsplash.com/CDC

Nine biopharmaceutical companies have signed a safety pledge, committing to "developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles."

AstraZeneca, BioNTech, Moderna, Pfizer, Novavax, Sanofi, GlaxoSmithKline, Johnson & Johnson and Merck have signed the pledge just a week after the CDC's vaccine distribution plans surfaced, suggesting a vaccine would be available by as early as late October.

Business • Health Care
Pfizer and BioNTech Covid-19 vaccine gets approved for second trial

Pfizer and BioNTech's Covid-19 vaccine BNT162b2 has been approved for its Phase II/III clinical trial by German Paul-Ehrlich-Institut. If the trials prove successful, Pfizer and BioNTech will try to seek regulatory approval as early as October.

"A large, controlled Phase III study is a crucial prerequisite to prove the safety and efficacy of a vaccine. The integration of sites in Europe, and now especially in Germany, is aimed at supporting an approval in Europe," so BioNTech CEO and co-founder Ugur Sahin.

Regional News • Europe • United Kingdom
UK Government Secures 60m More Doses of COVID-19 vaccine
Glaxo Smith Kline Offices on the Great West Road at Brentford
Glaxo Smith Kline Offices on the Great West Road at Brentford Credit: Maxwell Hamilton / Wikimedia Commons (Creative Commons Attribution ShareAlike 3.0)

The UK government signed a deal with drug giants GSK and Sanofi for 60 million doses of an experimental COVID-19 vaccine. This is the country's fourth COVID-19 vaccination deal. The UK previously secured 100m doses from AstraZeneca and 90m doses from the alliance between Valneva, BioNtech and Pfizer.

Science • Medicine
Pfizer and US reach $1.95 billion deal for Covid-19 vaccine
Pfizer and US reach $1.95 billion deal for Covid-19 vaccine
Credit: Rhoda Baer (Photographer) / Public domain

The US government has agreed to pay $1.95 billion for 100 million Covid-19 vaccine doses to American pharmaceutical company Pfizer and German biotechnology company. The vaccine called BNT162 is currently still in development and early clinical trials. The agreement further states that the US could buy another 500 million doses, provided that the vaccine is both safe and effective as well as approved b the US Food and Drug Administration.